Simon Tarsh's most recent trade in Renovaro Biosciences Inc was a trade of 58,500 Option to purchase shares of common stock done . Disclosure was reported to the exchange on Nov. 4, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Renovaro Biosciences Inc | Simon Tarsh | Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2024 | 58,500 | 58,500 | - | - | Option to purchase shares of common stock | |
Onconetix Inc | Simon Tarsh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2024 | 3,318 | 3,477 | - | 0 | Common Stock | |
Renovaro Biosciences Inc | Simon Tarsh | Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2024 | 10,000 | 10,000 | - | - | Option to purchase shares of common stock | |
Blue Water Biotech Inc | Simon Tarsh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 6,360 | 6,360 | - | 0 | Common Stock | |
Blue Water Biotech Inc | Simon Tarsh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Aug 2022 | 4,073 | 4,073 | - | - | Stock Option |